| 前收市價 | 0.4500 |
| 開市 | 0.5500 |
| 買盤 | 0.4000 |
| 賣出價 | 0.5500 |
| 拍板 | 2.50 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 0.4700 - 0.5500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 541 |
ZacksRevance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revance Therapeutics (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
InvestorPlaceThe 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:PIPR) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. Piper Sandler may be the best bet for investors especially when you see
InvestorPlace3 Underappreciated Stocks That Could 10x in 10 Years
Like achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter Lynch, these stocks are innovators with the potential to grow exponentially. Indeed, 10x stocks are market disrupters and innovators. And they create products people love. Today, I’m on the hunt for three potential 10x stocks to result in a home run. To come up with the list, I screened for the following criteria: Small-mid cap stocks ($300 mill
